Cencora/$COR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cencora

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Ticker

$COR

Primary listing

NYSE

Industry

Health Care Providers & Services

Employees

44,000

ISIN

US03073E1055

Cencora Metrics

BasicAdvanced
$58B
34.92
$8.59
0.60
$2.16
0.73%

What the Analysts think about Cencora

Analyst ratings (Buy, Hold, Sell) for Cencora stock.

Bulls say / Bears say

Cencora's acquisition of RCA enhances its position in high-growth specialty pharmaceutical markets, potentially driving significant revenue growth. (Investing.com)
The company's strong performance in the U.S. Healthcare sector, with a 14.69% revenue growth as of September 30, 2024, indicates robust operational efficiency and market demand. (Nasdaq)
Cencora's commitment to innovation, demonstrated by new products in inventory management and clinical trial support, positions it as a comprehensive partner in the pharmaceutical supply chain. (Investing.com)
BofA Securities downgraded Cencora's stock from Buy to Neutral, citing concerns over the company's ability to maintain double-digit EPS growth amid industry normalization. (Investing.com)
Cencora's high debt-to-equity ratio of 5.11 indicates a heavier reliance on borrowed funds, raising concerns about financial leverage and potential strain. (Benzinga)
The company's international segment has shown softer performance, with expectations of guidance reductions due to slow clinical trial activity, potentially impacting global growth prospects. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.

Cencora Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cencora Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs